A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy

BACKGROUND: To compare the first-in-class sodium glucose co-transporter 2 (SGLT2) inhibitor, dapagliflozin, with existing type 2 diabetes mellitus (T2DM) treatment options available within the European Union (EU) for add-on therapy to sulfonylureas (SUs). METHODS: A systematic review was conducted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Orme, Michelle, Fenici, Peter, Lomon, Isabelle Duprat, Wygant, Gail, Townsend, Rebecca, Roudaut, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085736/
https://www.ncbi.nlm.nih.gov/pubmed/25006351
http://dx.doi.org/10.1186/1758-5996-6-73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085736/
https://www.ncbi.nlm.nih.gov/pubmed/25006351
http://dx.doi.org/10.1186/1758-5996-6-73

Ejemplares similares